Fangzhou Valuation Multiples

Discover Fangzhou's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Bike24, Daiichi Co, Jade Group, SRP Groupe and more.

Fangzhou Overview

About Fangzhou

Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services, Wholesale and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.


Founded

2019

HQ

China

Employees

488

Website

jianke.com

Financials (LTM)

Revenue: $615M
EBITDA: $4M

EV

$67M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Fangzhou Financials

Fangzhou reported last 12-month revenue of $615M and EBITDA of $4M.

In the same LTM period, Fangzhou generated $94M in gross profit, $4M in EBITDA, and $2M in net income.

Revenue (LTM)


Fangzhou P&L

In the most recent fiscal year, Fangzhou reported revenue of $525M and EBITDA of $5M.

Fangzhou is profitable as of last fiscal year, with gross margin of 16%, EBITDA margin of 1%, and net margin of 0%.

See analyst estimates for Fangzhou
LTMLast FY202320242025202620272028
Revenue$615M$525M$361M$402M$525M
Gross Profit$94M$83M$72M$77M$83M
Gross Margin15%16%20%19%16%
EBITDA$4M$5M($26M)($123M)$5M
EBITDA Margin1%1%(7%)(31%)1%
EBIT Margin0%0%(1%)(28%)0%
Net Profit$2M$2M($29M)($127M)$2M
Net Margin0%0%(8%)(32%)0%
Net Debt-($29M)---

Financial data powered by Morningstar, Inc.

Fangzhou Stock Performance

Fangzhou has current market cap of $125M, and enterprise value of $67M.

Market Cap Evolution


Fangzhou's stock price is $0.09.

Fangzhou share price decreased by 83.4% in the last year.

See more trading valuation data for Fangzhou
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$67M$125M2.9%-4.5%-83.4%$0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Fangzhou Valuation Multiples

Fangzhou trades at 0.1x EV/Revenue multiple, and 18.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Fangzhou

EV / Revenue (LTM)


Fangzhou Financial Valuation Multiples

As of September 1, 2026, Fangzhou has market cap of $125M and EV of $67M.

Fangzhou has a P/E ratio of 80.1x.

LTMLast FY202320242025202620272028
EV/Revenue0.1x0.1x0.2x0.2x0.1x
EV/EBITDA18.3x13.1x(2.6x)(0.5x)13.1x
EV/EBIT50.4x39.1x(16.9x)(0.6x)39.1x
EV/Gross Profit0.7x0.8x0.9x0.9x0.8x
P/E80.1x71.2x(4.3x)(1.0x)71.2x
EV/FCF-6.9x27.2x29.0x6.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Fangzhou Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Fangzhou Margins & Growth Rates

Fangzhou grew revenue by 27% and EBITDA by 100% in the last fiscal year.

In the most recent fiscal year, Fangzhou reported gross margin of 16%, EBITDA margin of 1%, and net margin of 0%.

See estimated margins and future growth rates for Fangzhou

Fangzhou Margins

Last FY202420252026202720282029
Gross Margin16%19%16%15%
EBITDA Margin1%(31%)1%2%
EBIT Margin0%(28%)0%0%
Net Margin0%(32%)0%0%
FCF Margin2%1%2%-

Fangzhou Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth27%11%31%27%
Gross Profit Growth20%6%9%20%
EBITDA Growth100%374%(104%)100%
EBIT Growth(39%)2693%(102%)(39%)
Net Profit Growth(15%)334%(101%)(15%)
FCF Growth-(6%)323%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Fangzhou Operational KPIs

Fangzhou's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.2M for the same period.

Fangzhou's Rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Fangzhou's Rule of X is 68% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Fangzhou
LTMLast FY202320242025202620272028
Rule of 4036%28%---
Bessemer Rule of X89%68%---
Revenue per Employee-$1.1M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue11%11%12%13%11%
G&A Expenses to Revenue4%4%4%34%4%
R&D Expenses to Revenue--2%--
Opex to Revenue-16%21%47%16%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Fangzhou Competitors

Fangzhou competitors include Bike24, Daiichi Co, Jade Group, SRP Groupe, Komplett, Global Fashion Group, Autoserver Co, Nelly Group, Medifast and a.k.a. Brands.

Most Fangzhou public comparables operate across Consumer E-commerce, Pharmacies, Vertical E-commerce and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Bike240.4x0.4x7.5x6.6x
Daiichi Co0.2x0.2x4.6x-
Jade Group0.9x0.9x5.7x-
SRP Groupe0.2x0.2x(8.1x)(4.9x)
Komplett0.2x0.2x(15.1x)4.9x
Global Fashion Group0.1x0.1x(24.0x)3.0x
Autoserver Co1.4x1.4x3.3x-
Nelly Group0.8x0.8x4.9x5.6x

This data is available for Pro users. Sign up to see all Fangzhou competitors and their valuation data.

Start Free Trial

Fangzhou VC Funding History

Before going public, Fangzhou raised $281M in total equity funding, across 4 rounds.

Last private valuation of Fangzhou was $600M, after raising $130M in September 2018 from ShenZhen GTJA Investment Group, Crescent Point, and HBM Healthcare Investments.


Fangzhou Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
May-20Series CHBM Healthcare Investments$1M--
Sep-18Series BShenZhen GTJA Investment Group; Crescent Point; HBM Healthcare Investments$130M$600MJianke (Jianke.com) is an online pharmacy platform that raised a total of $280M across multiple rounds, with its latest reported funding being a Series B round of $130M on September 4, 2018, from investors including Crescent Point Group, HBM Healthcare Investments, and Shenzhen GTJA Investment Group, matching the query details. Jianke operated in China's online healthcare sector, focusing on medication orders through its platform.
Jan-17Series AAsia-Pac eCommerce; Volcanics Venture; YungPark Capital$50M-Jianke is a Chinese online pharmacy founded in 2006, operating as the second largest online drug store in China after 111.com as of June 2017, based on performance in the first half of 2016. It offers over 680,000 SKUs, has served more than 100 million customers cumulatively, and boasts a repeat purchase rate above 50%. The company runs a B2C e-commerce marketplace for medicines alongside brick-and-mortar hospitals. In 2017, it secured a US$50 million Series A+ round led by investors including Asia-Pac eCommerce, PGA Ventures, and Volcanics Capital, according to local media IT Ju Zi. Later, a Reuters report cited a source valuing Jianke between US$500-600 million ahead of a planned private fundraising and US IPO. Jianke's founder and CEO Fangmin Xie emphasized continued focus on B2C market growth amid rising consumer adoption of online pharmacies in China.
Jan-16Series ACrescent Point$100M-Jianke.com is a Chinese healthcare and pharmaceutical company that has raised capital through multiple funding rounds. The company went on to raise a Series A-II round on May 15, 2017, and a Series B round of $130 million on September 4, 2018, led by Crescent Point Group, HBM Healthcare Investments, and Shenzhen GTJA Investment Group.

Investments by Fangzhou

Fangzhou has invested in 1 company to date.

Latest investment by Fangzhou was on May 21st 2019. Fangzhou invested in Biofourmis in their $35M Series B round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Fangzhou

Biofourmis
Description
Biofourmis is a Boston-headquartered digital therapeutics company founded in 2015. It creates AI-driven software platforms combining biosensors and machine learning to personalize care for heart failure, COPD, and cancer patients. Biofourmis delivers remote monitoring tools to clinicians and cost-saving analytics to payers in the United States, Singapore, and India. The firm collaborates with hospitals like Mass General Brigham on large-scale deployments predicting clinical deteriorations for early interventions.
HQ CountryUnited States
HQ City
Boston, MA
Deal Date21 May 2019
RoundSeries B
Raised$35M
InvestorsSGInnovate; MMV Europe & Asia-Pacific; Openspace Capital; Fangzhou; EDBI; Aviva Ventures; Peak XV Partners
Valuation$250M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Fangzhou investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Fangzhou

When was Fangzhou founded?Fangzhou was founded in 2019.
Where is Fangzhou headquartered?Fangzhou is headquartered in China.
How many employees does Fangzhou have?As of today, Fangzhou has over 488 employees.
Who is the CEO of Fangzhou?Fangzhou's CEO is Fangmin Xie.
Is Fangzhou publicly listed?Yes, Fangzhou is a public company listed on HKEX.
What is the stock symbol of Fangzhou?Fangzhou trades under 06086 ticker.
When did Fangzhou go public?Fangzhou went public in 2024.
Who are competitors of Fangzhou?Fangzhou main competitors include Bike24, Daiichi Co, Jade Group, SRP Groupe, Komplett, Global Fashion Group, Autoserver Co, Nelly Group, Medifast, a.k.a. Brands.
What is the current market cap of Fangzhou?Fangzhou's current market cap is $125M.
What is the current revenue of Fangzhou?Fangzhou's last 12 months revenue is $615M.
What is the current revenue growth of Fangzhou?Fangzhou revenue growth (NTM/LTM) is 35%.
What is the current EV/Revenue multiple of Fangzhou?Current revenue multiple of Fangzhou is 0.1x.
What is the current EBITDA of Fangzhou?Fangzhou's last 12 months EBITDA is $4M.
What is Fangzhou's EBITDA margin?Fangzhou's last 12 months EBITDA margin is 1%.
What is the current EV/EBITDA multiple of Fangzhou?Current EBITDA multiple of Fangzhou is 18.3x.
How many companies Fangzhou has acquired to date?Fangzhou hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Fangzhou has invested to date?As of September 2026, Fangzhou has invested in 1 company.
In what companies Fangzhou invested in?Fangzhou invested in Biofourmis.

See public comps similar to Fangzhou

Lists including Fangzhou

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial